Sanofi and Regeneron's Latest Partnership

Pharmaceutical giant Sanofi and biotech Regeneron  have announced the start of two late-stage clinical trials for their experimental rheumatoid arthritis drug sarilumab. This antibody is being tested in combination with methotrexate, a drug often used for the treatment of rheumatoid arthritis, and will be compared to Amgen  and Pfizer's Enbrel. In the following video, health-care analyst Max Macaluso discusses these clinical trials and how this drug could compete in the rheumatoid arthritis market.
 

AbbVie's Humira is a leading rheumatoid arthritis medication, but investors in this relatively new company are left wondering what the future holds once this drug loses patent protection. The Fool's brand-new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.

 

The article Sanofi and Regeneron's Latest Partnership originally appeared on Fool.com.

Max Macaluso, Ph.D. has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Goal Setting

Want to succeed? Then you need goals!

View Course »

Professional Vs Do it Yourself Investing

Should you get advice or DYI?

View Course »

Add a Comment

*0 / 3000 Character Maximum